KIORA PHARMACEUTICALS INC
Retained, source-linked public records. Missing information does not imply that the company has no such information.
Security directory snapshot: 2026-11-17T21:43:52.460Z (not the page refresh time).
Company information and sources
CIK 0001372514
- Official website
- Not verified
- Business description
- Not verified
- Industry and source classification
- Not verified
- Jurisdiction of incorporation
- SEC DEI — Delaware
Evidence observed: 2026-10-29T11:16:19.812Z
Profile content revised: 2026-11-12 · Evidence - Business jurisdiction
- Not verified
- Country (consistent scope not assumed)
- Not verified
Specific securities
- KPHMW — Security type not verified
Market classification: Not verified
Classifications belong to individual securities. No principal security is selected for a company with multiple securities.
Retained announcements and disclosures
- · KPHMW · Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update · Original SEC filing
- · KPHMW · KIORA PHARMACEUTICALS INC files quarterly financial statements for the period ended 2026-09-30 · Original SEC filing
- · KPHMW · Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan · Original SEC filing
Open the complete company page and existing modules
Additional modules retain their existing access rules and may load separately.